Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
$37.56−0.19 (-0.50%)
Close on Nov 19, 2026Market cap $3.64BP/E –Yield –
Xenon Pharmaceuticals shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Xenon Pharmaceuticals's shares outstanding was 100M at Jun 30, 2026. For fiscal 2025 it was 79M, up 1.7% from the year before. Over ten years it grew 18.7% a year on average. The highest annual figure on record is 79M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 79M | +1.7% |
| FY2024 | Dec 31, 2024 | 78M | +16.5% |
| FY2023 | Dec 31, 2023 | 67M | +10.5% |
| FY2022 | Dec 31, 2022 | 61M | +38.8% |
| FY2021 | Dec 31, 2021 | 44M | +26.3% |
| FY2020 | Dec 31, 2020 | 35M | +33.2% |
| FY2019 | Dec 31, 2019 | 26M | +33.5% |
| FY2018 | Dec 31, 2018 | 19M | +7.9% |
| FY2017 | Dec 31, 2017 | 18M | +16.2% |
| FY2016 | Dec 31, 2016 | 15M | +8.5% |
| FY2015 | Dec 31, 2015 | 14M | +260.3% |
| FY2014 | Dec 31, 2014 | 4M | +97.3% |
| FY2013 | Dec 31, 2013 | 2M | +51.3% |
| FY2012 | Dec 31, 2012 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 100M | +26.2% |
| Q1 FY2026 | Mar 31, 2026 | 87M | +11.0% |
| Q4 FY2025 | Dec 31, 2025 | 80M | +2.2% |
| Q3 FY2025 | Sep 30, 2025 | 79M | +1.7% |
| Q2 FY2025 | Jun 30, 2025 | 79M | +1.7% |
| Q1 FY2025 | Mar 31, 2025 | 79M | +1.4% |
| Q4 FY2024 | Dec 31, 2024 | 78M | +12.0% |
| Q3 FY2024 | Sep 30, 2024 | 78M | +18.1% |
| Q2 FY2024 | Jun 30, 2024 | 78M | +17.9% |
| Q1 FY2024 | Mar 31, 2024 | 78M | +18.1% |
| Q4 FY2023 | Dec 31, 2023 | 70M | +6.6% |
| Q3 FY2023 | Sep 30, 2023 | 66M | +0.8% |
| Q2 FY2023 | Jun 30, 2023 | 66M | +17.2% |
| Q1 FY2023 | Mar 31, 2023 | 66M | +19.8% |
| Q4 FY2022 | Dec 31, 2022 | 66M | +23.1% |
| Q3 FY2022 | Sep 30, 2022 | 65M | +54.9% |
| Q2 FY2022 | Jun 30, 2022 | 56M | +33.5% |
| Q1 FY2022 | Mar 31, 2022 | 55M | +49.0% |
| Q4 FY2021 | Dec 31, 2021 | 53M | +52.3% |
| Q3 FY2021 | Sep 30, 2021 | 42M | +20.8% |
| Q2 FY2021 | Jun 30, 2021 | 42M | +20.3% |
| Q1 FY2021 | Mar 31, 2021 | 37M | +11.0% |
| Q4 FY2020 | Dec 31, 2020 | 35M | +32.4% |
| Q3 FY2020 | Sep 30, 2020 | 35M | +35.7% |
| Q2 FY2020 | Jun 30, 2020 | 35M | +35.7% |
| Q1 FY2020 | Mar 31, 2020 | 33M | +28.9% |
| Q4 FY2019 | Dec 31, 2019 | 26M | +4.6% |
| Q3 FY2019 | Sep 30, 2019 | 26M | +27.0% |
| Q2 FY2019 | Jun 30, 2019 | 26M | +80.2% |
| Q1 FY2019 | Mar 31, 2019 | 26M | +44.6% |
| Q4 FY2018 | Dec 31, 2018 | 25M | +40.4% |
| Q3 FY2018 | Sep 30, 2018 | 20M | +12.8% |
| Q2 FY2018 | Jun 30, 2018 | 14M | -20.6% |
| Q1 FY2018 | Mar 31, 2018 | 18M | -0.9% |
| Q4 FY2017 | Dec 31, 2017 | 18M | +0.6% |
| Q3 FY2017 | Sep 30, 2017 | 18M | +18.0% |
| Q2 FY2017 | Jun 30, 2017 | 18M | – |
| Q1 FY2017 | Mar 31, 2017 | 18M | – |
| Q4 FY2016 | Dec 31, 2016 | 18M | – |
| Q3 FY2016 | Sep 30, 2016 | 15M | – |
See a number that looks wrong?